|Bid||1.01 x 1100|
|Ask||1.31 x 1800|
|Day's Range||1.07 - 1.12|
|52 Week Range||0.88 - 3.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...
Key story highlights: Germantown biopharmaceutical company Neuralstem Inc. named Jim Scully interim CEO. The board also appointed William Oldaker, a member of the board since 2007, as chairman. Maryland stem cell therapy company Neuralstem Inc. (NASDAQ: CUR) has named Jim Scully interim CEO.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...
Neuralstem (NASDAQ:CUR) stock is on fire after revealing a huge clinical win that has sent bulls storming the market today to buy into piece of the biotech action. Shares are rocketing 100% on back of the drug maker's successful updated Phase 2 clinical data in major depressive disorder, where the company's NSI-189 asset impressed at the 56th American College of Neuropsychopharmacology (ACNP) Annual meeting.
Examining Neuralstem Inc’s (NASDAQ:CUR) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceedRead More...
On a per-share basis, the Germantown, Maryland-based company said it had a loss of 18 cents. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Cytokinetics, Incorporated, Geron Corporation, Acorda Therapeutics, Inc., Aceto Corporation, Intra-Cellular Therapies, Inc., Supernus Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. (CYTK-US, GERN-US, ACOR-US, ACET-US, ITCI-US, SUPN-US and ... Read more (Read more...)
For Neuralstem Inc’s (NASDAQ:CUR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...